B.Riley/FBR Downgrades Corcept Therapeutics (CORT) to Neutral
Tweet
Share
E-mailGet Alerts CORT Hot Sheet
Price: $23.46 -1.43%
Rating Summary:
9 Buy, 6 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 12 | Down: 28 | New: 29
Rating Summary:
9 Buy, 6 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 12 | Down: 28 | New: 29
Join SI Premium – FREE
Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.
B.Riley/FBR analyst David Buck downgraded Corcept Therapeutics (NASDAQ: CORT) from Buy to Neutral with a price target of $12.00.
For an analyst ratings summary and ratings history on Corcept Therapeutics click here. For more ratings news on Corcept Therapeutics click here.
Shares of Corcept Therapeutics closed at $11.18 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Morgan Stanley Downgrades Discover Financial (DFS) to Equalweight, 'Thesis Largely Played Out'
- Citi Downgrades Life Storage Inc. (LSI) to Neutral Following Takeover Bid
- William Blair Downgrades Oak Street Health (OSH) to Market Perform
Create E-mail Alert Related Categories
DowngradesRelated Entities
David BuckSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
